Filing Flows › Tango Therapeutics (TNGX) › R&D spending
Tango Therapeutics (TNGX) R&D spending by quarter
Tango Therapeutics' R&D spending was $30.8M in Q3 2025 (third quarter 2025), -6% from Q2 2025. Over the last 4 quarters it ranged from $30.8M (Q3 2025) to $36.4M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2025 | $30.8M | -6% | — |
| Q2 2025 | $32.8M | -10% | — |
| Q1 2025 | $36.4M | +7% | — |
| Q4 2024 | $33.9M | — | — |
Q3 2025 at a glance
Tango Therapeutics, Q3 2025: revenue $53.8M (+364% year over year), operating margin 26.2%, net earnings $15.9M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Tango Therapeutics' R&D spending?
Tango Therapeutics' R&D spending was $30.8M in Q3 2025 (third quarter 2025), -6% from Q2 2025.
How has Tango Therapeutics' R&D spending changed?
Over the last 4 quarters it ranged from $30.8M (Q3 2025) to $36.4M (Q1 2025).